Is OREX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,322 people get OREX articles and Market Currents by email alert.

Get email alerts on OREX »

HEADLINES:

Arena - Good Sales, Bad Sales, Long And Short
Spencer Osborne • Fri, May 24 • 29 Comments
Orexigen Therapeutics' CEO Presents at 2013 UBS Global Healthcare Services Conference (Transcript)
Wed, May 22
Orexigen Therapeutics to Present at the UBS Global Healthcare Conference

PR Newswire (May 17, 2013)
Orexigen Therapeutics' Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Wed, May 15
Vivus Starting To Gain The Advantage Over Arena
Equity Options Guru • Tue, May 14 • 112 Comments
Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

PR Newswire (May 10, 2013)
Orexigen Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013

PR Newswire (May 8, 2013)
Orexigen Therapeutics to Host First Quarter 2013 Financial Results Conference Call and Webcast

PR Newswire (May 2, 2013)
Vivus And Anti-Obesity Sector Benefit From New Insurance Deal
Spencer Osborne • Wed, May 1 • 52 Comments
Orexigen Therapeutics Commends the Campaign to End Obesity's Report on Long-term Returns of Obesity Prevention Policies

PR Newswire (Apr 25, 2013)
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential
Trade In Mexico • Wed, Apr 24 • 26 Comments
Arena Faces A Convergence Of DEA And European Decisions
Reasonable Risk • Wed, Apr 24 • 103 Comments
Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors

PR Newswire (Apr 22, 2013)
Vivus Seeing Traction With Qsymia
Spencer Osborne • Fri, Apr 19 • 59 Comments
Vivus Gets Restrictions Loosened
Spencer Osborne • Wed, Apr 17 • 94 Comments
Vivus May Get Second Wind On Qsymia
Spencer Osborne • Thu, Apr 11 • 89 Comments
Arena Applies For Launch In Mexico
Spencer Osborne • Mon, Apr 1 • 17 Comments
Should Anti-Obesity Drug Company Stocks Trade In Tandem?
Reasonable Risk • Mon, Apr 1 • 126 Comments
Vivus Adds Debt - Avoids Dilution
Spencer Osborne • Wed, Mar 27 • 50 Comments

To learn more about Seeking Alpha Pro, click here.

Adjust Accordingly: Orexigen's Catalysts May Be Later Than Hoped
PropThink • Tue, Mar 19 • 4 Comments
Key Dates For Arena And Orexigen Investors
Spencer Osborne • Wed, Dec 26, 2012 • 46 Comments
Orexigen: Is Contrave The Long-Term Winner In The Anti-Obesity Drug Wars?
EnhydrisPECorp • Mon, Dec 17, 2012 • 12 Comments
Orexigen: The Best Bet In Obesity For 2013
PropThink • Mon, Dec 17, 2012 • 13 Comments
Can Orexigan Benefit From Possible FDA Changes In Approval?
Spencer Osborne • Thu, Oct 11, 2012 • 6 Comments
Weight Loss Stocks In Action
Brian L. Wilson • Tue, Sep 25, 2012 • 12 Comments
Orexigen Starts Its Road Show - What The Slides Tell Us
Red Acre Investments • Thu, Sep 20, 2012 • 12 Comments
Earnings Preview: Orexigen Therapeutics
Vytautas Drumelis • Sat, Aug 4, 2012 • 3 Comments
Why The FDA's Approval Of Lorcaserin Is Bad News For Orexigen Therapeutics
Adam Gefvert • Thu, Jun 28, 2012 • 26 Comments
Orexigen: When To Buy?
Rx Stocks • Fri, Jun 22, 2012 • 6 Comments
Orexigen; FDA Reverses Position And Gives New Life To Contrave
Smith On Stocks • Wed, Sep 21, 2011 • 3 Comments
Orexigen Revisited: Chances for Contrave Approval Seem Slim
Smith On Stocks • Wed, Aug 10, 2011 • 3 Comments
Is Orexigen Therapeutics Still a Good Buy?
Michael Bryant • Mon, Feb 7, 2011 • 22 Comments
New Hurdle for Orexigen Diet Pill Has Investors Worried
The Burrill Report • Sun, Feb 6, 2011 • 5 Comments
Orexigen Options: A Lesson in Trading Biotech
Mark Mansfield • Tue, Feb 1, 2011 • 9 Comments
Trading Orexigen's PDUFA Event
Tony Pelz • Thu, Jan 27, 2011 • 10 Comments
Orexigen Therapeutics: A Safe Short on Likely Drug Rejection
Michael Bryant • Thu, Jan 27, 2011 • 45 Comments
A Look at Orexigen's Fair Value Today
Komodo Global • Thu, Jan 20, 2011 • 4 Comments
Eight Factors That May Impact Approval of Orexigen's Weight Loss Drug
Komodo Global • Thu, Jan 20, 2011 • 3 Comments
Orexigen Approval Shows That Diversification Strategy Can Work
Ruthanne Williams Roussel • Thu, Dec 9, 2010 • 7 Comments

Arena - Good Sales, Bad Sales, Long And Short
Spencer Osborne • Fri, May 24 • 29 Comments
Vivus Starting To Gain The Advantage Over Arena
Equity Options Guru • Tue, May 14 • 112 Comments
Vivus And Anti-Obesity Sector Benefit From New Insurance Deal
Spencer Osborne • Wed, May 1 • 52 Comments
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential
Trade In Mexico • Wed, Apr 24 • 26 Comments
Arena Faces A Convergence Of DEA And European Decisions
Reasonable Risk • Wed, Apr 24 • 103 Comments
Vivus Seeing Traction With Qsymia
Spencer Osborne • Fri, Apr 19 • 59 Comments
Vivus Gets Restrictions Loosened
Spencer Osborne • Wed, Apr 17 • 94 Comments
Vivus May Get Second Wind On Qsymia
Spencer Osborne • Thu, Apr 11 • 89 Comments
Arena Applies For Launch In Mexico
Spencer Osborne • Mon, Apr 1 • 17 Comments
Should Anti-Obesity Drug Company Stocks Trade In Tandem?
Reasonable Risk • Mon, Apr 1 • 126 Comments
Vivus Adds Debt - Avoids Dilution
Spencer Osborne • Wed, Mar 27 • 50 Comments
Painless Play To Fatten Up Your Portfolio: Buy Arena
Wall Street Artist • Mon, Mar 25 • 46 Comments
6 Reasons To Buy Arena Pharmaceuticals Right Now
Equity Options Guru • Fri, Mar 22 • 47 Comments
Arena Pharma Has Plump Profit Potential
Todd Johnson • Thu, Mar 14 • 52 Comments
Is Vivus Under Attack By First Manhattan Co.?
Spencer Osborne • Mon, Mar 11 • 52 Comments
Is Vivus' Run-Up Long Term?
Spencer Osborne • Thu, Mar 7 • 37 Comments
It's Now Time For Vivus Investors To Watch Arena Numbers
Spencer Osborne • Thu, Feb 28 • 60 Comments
Vivus, Arena, And Orexigen Investors Waiting On February 25
Spencer Osborne • Fri, Feb 22 • 35 Comments
Athersys: The Coming Year Will Define MultiStem, Its Adult Stem Cell Product
Smith On Stocks • Fri, Feb 8 • 19 Comments
Obesity Drug Stocks Trade Weaker In 2013
Brian L. Wilson • Thu, Feb 7 • 6 Comments

Orexigen Therapeutics' CEO Presents at 2013 UBS Global Healthcare Services Conference (Transcript)
Wed, May 22
Orexigen Therapeutics' Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Wed, May 15
Orexigen Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
Orexigen Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Mar 13
Orexigen Therapeutics' CEO Presents at JPMorgan Global Healthcare Conference (Transcript)
Tue, Jan 8
Orexigen Therapeutics' CEO Hosts Analyst Day Conference (Transcript)
Tue, Dec 18, 2012
Orexigen Therapeutics' CEO Presents at Credit Suisse Group AG Healthcare Conference (Transcript)
Thu, Nov 15, 2012
Orexigen Therapeutics' Management Presents at Lazard Capital Markets 9th Annual Healthcare Conference (Transcript)
Tue, Nov 13, 2012
Orexigen Therapeutics' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Nov 7, 2012
Orexigen Therapeutics' CEO Discusses Company and Light Study Update Conference Call - Transcript
Mon, Oct 22, 2012 • 1 Comment
Orexigen Therapeutics' CEO Presents at Bank of America Merrill Lynch Global Healthcare Conference - Special Call Transcript
Thu, Sep 13, 2012
Orexigen Therapeutics' CEO Presents at Morgan Stanley Healthcare Conference (Transcript)
Wed, Sep 12, 2012
Orexigen Therapeutics CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 7, 2012
Orexigen Therapeutics, Inc. Q1 2010 Earnings Call Transcript
Mon, May 10, 2010 • 1 Comment
Orexigen Therapeutics Q4 2007 Earnings Call Transcript
Mon, Mar 31, 2008

Orexigen Therapeutics to Present at the UBS Global Healthcare Conference

PR Newswire (May 17, 2013)
Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

PR Newswire (May 10, 2013)
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013

PR Newswire (May 8, 2013)
Orexigen Therapeutics to Host First Quarter 2013 Financial Results Conference Call and Webcast

PR Newswire (May 2, 2013)
Orexigen Therapeutics Commends the Campaign to End Obesity's Report on Long-term Returns of Obesity Prevention Policies

PR Newswire (Apr 25, 2013)
Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors

PR Newswire (Apr 22, 2013)
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012

PR Newswire (Mar 13, 2013)
Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast

PR Newswire (Mar 7, 2013)
Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference

PR Newswire (Feb 28, 2013)
Orexigen Therapeutics to Present at Upcoming Investor Conferences

PR Newswire (Feb 7, 2013)
Orexigen Therapeutics Announces Progress with FDA on a Faster Path to Resubmission of the Contrave NDA

PR Newswire (Jan 7, 2013)
Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the JP Morgan Healthcare Conference

PR Newswire (Dec 24, 2012)
Orexigen Therapeutics Concludes Light Study Patient Screening, Expecting to Randomize Approximately 9,000 Patients, and Presents New Obesity Therapeutics Market Research

PR Newswire (Dec 18, 2012)
Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012

PR Newswire (Dec 4, 2012)
David Endicott Joins Orexigen Therapeutics Board of Directors

PR Newswire (Nov 30, 2012)
Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences

PR Newswire (Nov 8, 2012)
Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012

PR Newswire (Nov 7, 2012)
Orexigen Therapeutics Schedules November 7, 2012 Conference Call and Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2012

PR Newswire (Oct 31, 2012)
Orexigen® Therapeutics Prices Public Offering of Common Stock

PR Newswire (Oct 25, 2012)
Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock

PR Newswire (Oct 24, 2012)

OREX vs. ETF Alternatives

Company Description

We were incorporated in Delaware in September 2002. Our principal offices are located at 3344 N. Torrey Pines Court, Suite 200, La Jolla, California 92037, and our telephone number is (858) 875-8600. Our website address is www.orexigen.com. Information found on, or accessible through, our... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 8, 6:43 PM Orexigen (OREX): Q1 EPS of -$0.21 beats by $0.13. Revenue of $857K misses by $33.K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, March 28, 5:36 PM After-hours top gainers, as of 5:15 p.m.: LODE +3.8%. CWH +2.5%. VRNG +1.9%. EBR +1.8%. ZOLT +1.7%.
After-hours top losers: RRMS -3.3%. SPIL -3.2%. OREX -1.7%. NUGT -1.4%. LDP -1.4%. Comment! [On the Move]
Thursday, March 28, 5:21 PM Bacteria that live in the gut change after gastric-bypass surgery and may aid in weight loss, according to a recent study. Gastric surgery helps people lose weight by shrinking the size of the stomach and making it tougher to absorb calories, now scientists think it may also adjust gastrointestinal bacteria, contributing to weight loss and raising the possibility for less-drastic obesity treatment. 7 Comments [Healthcare]
Thursday, March 14, 3:30 PM Shares of Orexigen (OREX -4.8%) slip deeper into the red today after it reported a Q4 that beat on a per share basis, but came up short on revenue. The company reported a loss of $0.41 per share, versus the consensus of a $0.44 per share loss. Revenues were $857K, below analyst estimates of $890K. Total operating expenses were significantly higher for the quarter, coming in at $33.3M compared to $5.2M in Q411, reflecting higher R&D expenses associated with the conduct of its Contrave cardiovascular outcomes trial. Read more on earnings here: Earnings Call Transcript. 1 Comment [Healthcare, Earnings, On the Move]
Tuesday, December 18, 2012, 1:06 PM Orexigen Therapeutics (OREX -2.6%) has completed the screening of new patients for its Light Study trial to evaluate its obesity drug Contrave. About 9K patients will be randomized in the study within the next few weeks. OREX anticipates resubmiting the Contrave New Drug Application and conducting the interim analysis in 2013, with potential approval as early as fourth quarter 2013. Comment! [Healthcare, On the Move]
Wednesday, November 21, 2012, 10:40 AM Weight loss drug makers get a lift today after Aetna (AET -0.6%) revises its criteria under which the insurer considers weight reduction medications as "medically necessary" for treatment of obesity. In a Clinical Policy Bulletin revision dated yesterday, AET identified certain medications that have been approved by the FDA for weight reduction which would be covered under its policy: Qsymia, marketed by VIVUS (VVUS +13.2%), Belviq from Arena Pharmaceuticals (ARNA +2.9%), Didrex from Pfizer (PFE +0.1%), Xenical from Roche (RHHBY +0.3) and GlaxoSmithKline's (GSK +0.2%) Alli. Orexigen (OREX +6.5%), although not named in the bulletin, is also higher on the news. 11 Comments [Healthcare, On the Move]
Thursday, October 25, 2012, 10:16 AM Orexigen (OREX +3.4% to $5.71) prices an offering of 11M shares at $5.50, just below yesterday's close of $5.52. Net proceeds will be $56.5M, while there's also a greenshoe option of 1.65M shares. The offering comes just days after Orexigen said the FDA supports speeding up the application for weight loss pill Contrave. Comment! [Healthcare, On the Move]
Monday, October 22, 2012, 9:30 AM The FDA supports exploring with Orexigen Therapeutics (OREX +4.9%) how the firm can speed up its application for weight loss pill Contrave. The FDA rejected the drug in January 2011, due to possible heart problems, and asked Orexigen to conduct another study. The company has so far enrolled 7,000 patients and intends to recruit another 9,000 by the year-end. (PR) 1 Comment [Healthcare, On the Move]
Monday, October 22, 2012, 9:10 AM Premarket gainers: PGRX +42%. SUPN +16%. SVU +7%. ACOM +8%. OREX +7%. NBG +6%. BTU +6%. PHG +6%. GIVN +6%.
Losers: OSG -50%. NXY -7%. Comment! [On the Move]
Thursday, September 6, 2012, 3:54 PM Shares of Orexigen (OREX +16.7%) are soaring after Credit Suisse initiates coverage with an Outperform, saying it likes the prospects of a trial that will look at the cardiovascular impact of Contrave. Leerink Swann also recommends investors buy it aggressively. Meanwhile, it starts Arena Pharmaceutical (ARNA -4.6%) with an Underperform , saying Belviq may not generate enough revenue to justify the stock's current valuation. 22 Comments [Healthcare, On the Move]
Thursday, September 6, 2012, 9:10 AM Premarket gainers: IMUC +14%. MW +11%. OREX +10%. ARCT +8%. SHLD +7%. NAV +7%.
Losers: OCZ -30%. PAY -11%. WCRX -10%. Comment! [On the Move]
Wednesday, September 5, 2012, 9:28 AM Orexigen Therapeutics (OREX) +4.7% premarket as the drug developer says it will close enrollment of new patients into its study of cardiovascular risks associated with its weight-loss treatment Contrave in Q4, sooner than expected. The move could cut in half the time needed before performing an interim analysis of the data. Comment! [Healthcare, On the Move]
Wednesday, July 18, 2012, 8:40 AM Vivus (VVUS) shares are predictably chomping at the bit premarket, surging 13.3% after the FDA yesterday approved its weight-loss drug Qnexa/Qsymia. Shares had fallen sharply prior to the announcement. Also this morning, rivals Arena (ARNA) -5.9% and Orexigen Therapeutics (OREX) +3.2%. 13 Comments [On the Move, Healthcare]
Tuesday, July 17, 2012, 8:14 PM Other drug stocks reacting after hours to the FDA's approval of Vivus' (VVUS) Qnexa/Qsymia: OREX +6.4%, ARNA -6.7%. 26 Comments [Healthcare, On the Move]
Wednesday, July 11, 2012, 9:10 AM Premarket gainers: OMPI +8%. OREX +7%.
Losers: HGG -30%. OCZ -20%. PSEC -7%. KOF -6%. GG -6%. BBY -6%. Comment! [On the Move]
Monday, July 2, 2012, 9:10 AM Premarket gainers: CELL +64%. LNCR +21%. AMPE +17%. ATPG +13%. WFR +9%. AMLN +9%. MU +7%.
Losers: ANH -6%. OREX -5%. CORT -5%. Comment! [On the Move]

Joe Springer
Insider's showing their hands: http://bit.ly/TuYnnJ $MNKD $ARIA $VRTX $OREX $FOLD $ZLTQ $ISIS
10/17/12
Reply (4)

• !Report Abuse
View all 4 replies
mark woods: Did you say FOLD had strong insider selling or buying?
10/18/12
• !Report Abuse
Joe Springer: Hey Mark - Buying http://bit.ly/U9xCdG
10/18/12
• !Report Abuse
Add a reply...

140 characters

Michael Clark
NEW TRADING SHORT POSITIONS: AONEQ.PK, ARNA, BMI, LXRX, OREX http://seekingalpha.com/p/j3xv
7/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Fuinhaz $SPY morning update for July 23, 2012 http://bit.ly/Obv2iU SPY OREX PETM GMCR MON
7/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

FortSumter
OPEX today. Lesson learned on OREX. Shorted ARNA pop but misjudged length of time to drop. Bad timing = lost money. #study
7/20/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

FortSumter
Die OREX die. Go down another $3 and make me some money on my puts. Fat chance of that I think. Get it, "fat chance"?
7/18/12
Reply (1)

• !Report Abuse
View all 1 replies
JayWright: lol
7/18/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/NsftDv Premarket gainer $DGIT (23%), $MAT ( 7%), $OREX (5%), GS (2%)
7/17/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

whitehead1
OREX getting close to short territory.
7/16/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
I have an new article out this morning at http://seekingalpha.com/a/fh81 $OMPI $AMRN $ARNA $VVUS $OREX
7/16/12
Reply (13)

• !Report Abuse
View all 13 replies
Scott Matusow: i dont like to give opinions on shorting unless I am 100 percent sure, and I am not on VVUS, shorting is very risky.
7/18/12
• !Report Abuse
Maria Auziliadora: stockguy You buy wherever you want
7/19/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
I find it interesting Orexigen Therapeutics' (OREX) estimates were raised eventhough it has no drug on market. Or am I missing something?
7/16/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: http://bit.ly/MbO6xp
7/16/12
• !Report Abuse
Add a reply...

140 characters

FortSumter
Biggest flop of the month = OREX. Shorting via puts after ARNA approval. Will expire worthless. Lucky it was a small gamble <$1k for lunch.
7/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Joe Springer
Insider's showing their hands: http://bit.ly/TuYnnJ $MNKD $ARIA $VRTX $OREX $FOLD $ZLTQ $ISIS
10/17/12
Reply (4)

• !Report Abuse
View all 4 replies
mark woods: Did you say FOLD had strong insider selling or buying?
10/18/12
• !Report Abuse
Joe Springer: Hey Mark - Buying http://bit.ly/U9xCdG
10/18/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I have an new article out this morning at http://seekingalpha.com/a/fh81 $OMPI $AMRN $ARNA $VVUS $OREX
7/16/12
Reply (13)

• !Report Abuse
View all 13 replies
Scott Matusow: i dont like to give opinions on shorting unless I am 100 percent sure, and I am not on VVUS, shorting is very risky.
7/18/12
• !Report Abuse
Maria Auziliadora: stockguy You buy wherever you want
7/19/12
• !Report Abuse
Add a reply...

140 characters

FortSumter
Die OREX die. Go down another $3 and make me some money on my puts. Fat chance of that I think. Get it, "fat chance"?
7/18/12
Reply (1)

• !Report Abuse
View all 1 replies
JayWright: lol
7/18/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
I find it interesting Orexigen Therapeutics' (OREX) estimates were raised eventhough it has no drug on market. Or am I missing something?
7/16/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: http://bit.ly/MbO6xp
7/16/12
• !Report Abuse
Add a reply...

140 characters

JayWright
SA article read "OREX soars on back of Belviq" WTF?? OREX soar on someone else's spotlight and ARNA down almost 13%???
6/28/12
Reply (2)

• !Report Abuse
View all 2 replies
Tito1218: doesn't seem right does it...
6/28/12
• !Report Abuse
JayWright: no it doesnt...stock market, i hate you...but i need you.
6/28/12
• !Report Abuse
Add a reply...

140 characters

Adam Gefvert
I'm short OREX, ARNA's approval is actually a bad sign for them.
6/27/12
Reply (9)

• !Report Abuse
View all 9 replies
Adam Gefvert: Yea, it's having a good day now. Biotech is tough.
6/28/12
• !Report Abuse
Adam Gefvert: ARNA wasy down, go figure.
6/28/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Both Orexigen Therapeutics (OREX) & Arena Pharmaceuticals (ARNA) surged Tuesday as ARNA's FDA decision date nears.
6/13/12
Reply (22)

• !Report Abuse
View all 22 replies
Maria Auziliadora: Michael VVUS CEO bought some ARNA and I looks like is options of course he didn't buy the 50K that he sold of VVUS advertising costs $$
6/18/12
• !Report Abuse
Maria Auziliadora: and neither one of these companies have sold a pill yet until it gets passed
6/18/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/K0E0ZY Premarket Gainer ARNA NVDA OREX LEAP Loser CECO(7%), NUAN(5%), WWWW(3.61%), PCLN(2%), JPM(8%), JWN(5%), C(3%
5/11/12
Reply (3)

• !Report Abuse
View all 3 replies
freefdawatchlist: PCLN rallied $14 and then down $9, monday is a bullish day so definitely PCLN will rally
5/12/12
• !Report Abuse
Maria Auziliadora: Great!!!
5/12/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
ARNA, OREX, VVUS in trouble. BMY Bydureon works with qweek and qmonthly dosing! And it treats DM.
12/22/11
Reply (1)

• !Report Abuse
View all 1 replies
John Rayhall: Moral of the story is eat right and go to the gym FDA is going to be hard on teh fat loss drugs.
12/22/11
• !Report Abuse
Add a reply...

140 characters

OREX Orexigen Therapeutics, Inc.

OREX

Orexigen Therapeutics, Inc.